Browsing by Author "Johnny Mahlangu"
Now showing 1 - 20 of 36
- Results Per Page
- Sort Options
Item Application fo fa hemophila mortality framework to the Emicizumab Global Safety DatabaseFlora Peyvandi; Johnny Mahlangu; Steven Pipe; Charles Hay; Glenn Pierce; Peter Kuebler; R Kruse-Jarres; M ShimaItem Bleeding events and safety outcomes in persons with haemophilia A with inhibitors A prospective multicentre noninterventional studyJohnny Mahlangu; J Oldenburg; Michael Callaghan; Midori Shima; Elena Santagostino; E et alItem Diagnosis and treatment challenges in lower resource countries State of the art(WILEY-BLACKWELL) Johnny Mahlangu; S Diop; Michelle LavinItem Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis(WILEY-BLACKWELL) S Pipe; Ben Trzaskoma; Miranda Minhas; M Lehle; Johnny Mahlangu; E et alItem Efficacy safety and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr81 trialA Leavitt; Johnny Mahlangu; P Raheja; E Symington; D Quon; E et alItem Emicizumab in people with moderate or mild haemophilia AHAVEN 6 a multicentre open label singlearm phase 3 study(WILEY-BLACKWELL) C Negrier; Johnny Mahlangu; M Lehle; P Chowdary; Olivier Catalani; E et alItem Emicizumab is efficacious in people with Hemophilia A with comordities aged less than 50 years analysis of 4 phase III trials(WILEY-BLACKWELL) Víctor Jimenez-Yuste; Johannes Oldenburg; Eunice Tzeng; Elise Lim; Fabian Sanabria; Johnny MahlanguItem Emicizumab is well tolerated and effective in people with congenital haemophila A regardless of age severity of disease or inhibitor status a scoping review(WILEY-BLACKWELL) G Young; S Pipe; G Kenet; J Oldenburg; E et al; Johnny MahlanguItem Eptacog beta for the management of patients with hemophilia A and B with inhibitors A European perspective(WILEY-BLACKWELL) Wolfgang Miesbach; Manuel Carcao; Johnny Mahlangu; Yesim Dargaud; Victor Jimenez-Yuste; Cédric HermansItem FRONTIER 1 a partially randomized phase 2 study assessing the safetypharmacokinetics and pharmacodynamics of Mim8 a factor VIIIa mimetic(WILEY-BLACKWELL) S Lentz; P Chowdary; L Gil; F Lopez-Jaime; Johnny Mahlangu; E et alItem FRONTIER1 a partially randomized phase 2 study assessing the safety pharmacokinetics and pharmacodynamics of Mim8 a factor VIIa mimetic(WILEY-BLACKWELL) S Lentz; P Chowdary; Lidia Gil; Franciso J Lopez-Jaime; Johnny Mahlangu; E et alItem Gene therapy access: Global challenges, opportunities, and views from Brazil, South Africa and IndiaKenneth Cornetta; Martin Bonamino; Johnny Mahlangu; Federico Mingozzi; S Rangarajan; J RaoItem Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1(WILEY-BLACKWELL) Brian O' Mahony; Amy L Dunn; Andrew D Leavitt; F Peyvandi; Johnny Mahlangu; E et alItem Healthrelated quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors A non interventional studyJ Oldenburg; Huyen Tran; Flora Peyvandi; Ramiro Nunez; Peter Trask; S Chebon; Johnny Mahlangu; M Lehle; V JIMENEZ-YUSTE; S Von MackensenItem Immunoglobulin subtying and quantification in direct antiglobun test positive heamolysis in an HIVprevalent settingThirosha Chetty; Nikki Bouwer; Yuen On Wan; Johnny MahlanguItem Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion proteinJ Oldenburg; R Kulkarni; A SRIVASTAVA; Johnny Mahlangu; V BLANCHETTE; E et alItem Long term outcomes with emicizumab in hemophilia A without inhibitors result from HAVEN 3 and 4 studies(WILEY-BLACKWELL) Johnny Mahlangu; Víctor Jimenez-Yuste; Giuliana Ventriglia; Markus Niggli; Simona Barlera; E et alItem Managing surgery in hemophilia with recombinant factor VII Fc and factor IX Fc Data on safety and effectiveness from phase 3 pivotal studiesP Chowdary; Margareta Holmstrom; Johnny Mahlangu; M OZELO; I Pabinger; E et alItem Molecular Therapy(WILEY-BLACKWELL) K Cornetta; Samantha Kay; Florence Urio; Irene Kida Minja; Erasto Mbugi; Teddy Mselle; Siana Nkya; Mohamed Zahir Alimohamed; Kinuma Ndaki; Johnny MahlanguItem Outcomes and management of invasive procedures in participants with hemophilia A post gene therapy a post hoc analysis of the GENEr81 phase III trialD Quon; J Wang; M Wang; D Pepperell; Johnny Mahlangu; E et al